NBIX

NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change -1.46
Percentage change -1.08	%

Peers: VRTX REGN BIIB GILD INCY ALNY EXEL IONS SAGE ACAD

| Held by: IJH VTI VB VXF VBK XBI MDY USMV IBB IJK

Scroll to Statements

Index	-	P/E	45.25	EPS (ttm)	2.95	Insider Own	3.54%	Shs Outstand	99.00M	Perf Week	3.37%
Market Cap	13.21B	Forward P/E	22.52	EPS next Y	5.93	Insider Trans	-10.07%	Shs Float	95.47M	Perf Month	6.96%
Enterprise Value	12.76B	PEG	1.32	EPS next Q	0.97	Inst Own	94.57%	Short Float	3.70%	Perf Quarter	40.07%
Income	305.80M	P/S	5.47	EPS this Y	18.51%	Inst Trans	0.88%	Short Ratio	2.77	Perf Half Y	-2.97%
Sales	2.41B	P/B	5.21	EPS next Y	51.99%	ROA	8.54%	Short Interest	3.53M	Perf YTD	-2.23%
Book/sh	25.61	P/C	14.00	EPS next 5Y	34.35%	ROE	12.43%	52W High	157.98 -15.52%	Perf Year	-6.87%
Cash/sh	9.53	P/FCF	26.83	EPS past 3/5Y	53.21% 53.47%	ROIC	10.25%	52W Low	84.23 58.45%	Perf 3Y	40.19%
Dividend Est.	-	EV/EBITDA	24.08	Sales past 3/5Y	27.61% 24.48%	Gross Margin	97.77%	Volatility	2.30% 2.19%	Perf 5Y	4.54%
Dividend TTM	-	EV/Sales	5.29	EPS Y/Y TTM	-19.24%	Oper. Margin	20.78%	ATR (14)	2.96	Perf 10Y	182.10%
Dividend Ex-Date	Dec 29, 1995	Quick Ratio	3.02	Sales Y/Y TTM	21.73%	Profit Margin	12.68%	RSI (14)	67.75	Recom	1.37
Dividend Gr. 3/5Y	- -	Current Ratio	3.13	EPS Q/Q	-81.59%	SMA20	4.36%	Beta	0.25	Target Price	161.00
Payout	0.00%	Debt/Eq	0.19	Sales Q/Q	11.12%	SMA50	8.34%	Rel Volume	0.56	Prev Close	134.92
Employees	1800	LT Debt/Eq	0.18	Earnings	Jul 30 AMC	SMA200	9.54%	Avg Volume	1.28M	Price	133.46
IPO	May 23, 1996	Option/Short	Yes / Yes	EPS/Sales Surpr.	-85.05% 2.32%	Trades		Volume	714,747	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Initiated	Goldman	Buy	$182
Apr-15-25	Upgrade	Needham	Hold → Buy	$138
Apr-14-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$137
Feb-11-25	Initiated	Deutsche Bank	Hold	$138
Oct-10-24	Resumed	Raymond James	Outperform	$155
Aug-29-24	Upgrade	Piper Sandler	Neutral → Overweight	$131 → $159
Apr-24-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$140 → $170
Dec-13-23	Resumed	Citigroup	Neutral	$127
Dec-12-23	Initiated	Deutsche Bank	Buy	$136
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight	$135 → $140
Aug-21-23	Reiterated	Mizuho	Neutral	$112 → $113
Jul-24-23	Upgrade	SVB Securities	Market Perform → Outperform	$115 → $125
Jul-06-23	Upgrade	BMO Capital Markets	Underperform → Market Perform	$91 → $96
May-04-23	Upgrade	Guggenheim	Neutral → Buy	$145
Mar-30-23	Upgrade	Canaccord Genuity	Hold → Buy	$124 → $132
Mar-03-23	Upgrade	Evercore ISI	In-line → Outperform	$130
Feb-03-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$120 → $130
Nov-14-22	Downgrade	Evercore ISI	Outperform → In-line	$140 → $130
Oct-11-22	Initiated	UBS	Buy	$136
Sep-26-22	Initiated	Wells Fargo	Equal Weight	$110

Show Previous Ratings

Jul-10-25 11:26PM	Untapped Patient Base, Ingrezza Growth Keep Neurocrine (NBIX) on Guggenheim's Buy List (Insider Monkey)
08:00AM	Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity (Investor's Business Daily)
Jul-09-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results (PR Newswire)
Jun-30-25 04:05PM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist (PR Newswire)
Jun-29-25 08:36AM	3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking (MarketBeat)
08:30AM	Loading…
Jun-27-25 08:30AM	Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA (valbenazine) Capsules for Huntington's Disease Chorea (PR Newswire)
Jun-23-25 11:40AM	EGO or AEM: Which Is the Better Value Stock Right Now? (Zacks)
11:40AM	CPRX vs. NBIX: Which Stock Is the Better Value Option? (Zacks)
Jun-20-25 08:30AM	Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia (PR Newswire)
Jun-17-25 06:20AM	Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)? (Zacks)
Jun-12-25 06:20AM	Should You Invest in the SPDR S&P Biotech ETF (XBI)? (Zacks)
Jun-09-25 04:05PM	Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer (PR Newswire)
Jun-03-25 11:40AM	CPRX or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
Jun-02-25 08:30AM	Neurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO Study Demonstrating INGREZZA (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia (PR Newswire)
May-30-25 04:30PM	Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors (GlobeNewswire)
12:03AM	Loading…
May-29-25 12:03AM	Neurocrine Biosciences, Inc. (NBIX)'s M4 Agonist Shows Promise in Schizophrenia Phase 2 Trial, Phase 3 Launched (Insider Monkey)
May-28-25 04:05PM	Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025 (PR Newswire)
May-27-25 06:20AM	Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? (Zacks)
May-26-25 06:20AM	Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now? (Zacks)
May-20-25 06:20AM	Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now? (Zacks)
May-16-25 08:30AM	Neurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting (PR Newswire)
08:25AM	Neurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia (PR Newswire)
May-15-25 04:05PM	Neurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY (crinecerfont) (PR Newswire)
11:40AM	GRFS or NBIX: Which Is the Better Value Stock Right Now? (Zacks)
May-14-25 04:05PM	Neurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia (PR Newswire)
May-13-25 03:48PM	Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Ken Griffin's Midcap Stock Picks with Huge Upside Potential (Insider Monkey)
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
06:20AM	Should Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) Be on Your Investing Radar? (Zacks)
May-08-25 08:30AM	Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst Pediatric Study Demonstrating CRENESSITY Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups (PR Newswire)
May-07-25 03:34AM	Why Neurocrine Biosciences, Inc. (NBIX) Skyrocketed On Tuesday (Insider Monkey)
04:40PM	Loading…
May-06-25 04:40PM	Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug (Investor's Business Daily) +8.36%
04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in May (PR Newswire)
08:36AM	Q1 2025 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
08:30AM	Neurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie Awareness Campaign for People with Tardive Dyskinesia (PR Newswire)
06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks)
03:05AM	Neurocrine Biosciences Inc (NBIX) Q1 2025 Earnings Call Highlights: Strong INGREZZA Sales and ... (GuruFocus.com)
May-05-25 08:33PM	Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:30PM	Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
05:10PM	Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates (Zacks)
04:09PM	Neurocrine: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance (PR Newswire)
08:30AM	Neurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia (PR Newswire)
May-01-25 07:18AM	Neurocrine begins Phase III programme for schizophrenia treatment (Clinical Trials Arena)
Apr-30-25 11:43AM	Neurocrine Biosciences, Inc. (NBIX): Among Billionaire Cliff Asness' Stock Picks with Huge Upside Potential (Insider Monkey)
08:00AM	Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia (PR Newswire)
Apr-29-25 10:01AM	Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-28-25 10:00AM	Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards? (Zacks)
Apr-24-25 04:05PM	Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry (PR Newswire)
Apr-22-25 06:05PM	Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025 (Seeking Alpha)
Apr-16-25 05:51PM	Neurocrine Biosciences: Recent Selloff Has Created A Potential Buying Opportunity (Seeking Alpha)
Apr-14-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results (PR Newswire)
Apr-07-25 11:39AM	Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options (Zacks)
Apr-04-25 08:00AM	Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer (PR Newswire) -7.03%
Mar-31-25 04:03PM	Impax Small Cap Fund Q4 2024 Commentary (Seeking Alpha)
08:30AM	Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia (PR Newswire)
Mar-28-25 03:59PM	Baird Q4 2024 Small/Mid Cap Growth Equity Commentary (Seeking Alpha)
Mar-27-25 07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 07:00PM	Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential (Motley Fool)
Mar-25-25 06:20AM	Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now? (Zacks)
Mar-20-25 01:45PM	Neurocrine Biosciences debuts new data for effectiveness of Ingrezza (Clinical Trials Arena)
09:05AM	Invesco Health Care Fund Q4 2024 Commentary (SeekingAlpha)
08:30AM	Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA (valbenazine) Capsules (PR Newswire)
Mar-18-25 05:15AM	Neurocrine Biosciences (NBIX): Among the Best Biotech Stocks to Buy According to Billionaires (Insider Monkey)
Mar-17-25 08:30AM	Neurocrine Biosciences Presents New KINECT-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA (valbenazine) Capsules (PR Newswire)
Mar-14-25 05:30AM	Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. (The Wall Street Journal)
Mar-11-25 04:01PM	Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum (PR Newswire)
Mar-06-25 07:26AM	Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults (Clinical Trials Arena)
Mar-05-25 08:30AM	Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults (PR Newswire)
Feb-27-25 04:05PM	Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO Study for INGREZZA (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures (PR Newswire)
Feb-25-25 04:01PM	Neurocrine Biosciences to Present at Upcoming Investor Conferences in March (PR Newswire)
Feb-21-25 03:11PM	Is Neurocrine Biosciences (NBIX) One of the Best Fast Growth Stock to Buy Right Now? (Insider Monkey)
08:00AM	Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program (PR Newswire)
Feb-18-25 04:08PM	Neurocrine (NBIX): Among Top Insider Stock Buys And Sells In January (Insider Monkey)
Feb-10-25 06:18PM	Why Neurocrine Biosciences Stock Sank Today (Motley Fool)
08:32AM	Why Neurocrine Biosciences Inc. (NBIX) Crashed Last Week (Insider Monkey)
Feb-08-25 11:01AM	Here's Why Neurocrine Biosciences Inc. (NBIX) Crashed on Friday (Insider Monkey)
Feb-07-25 04:43PM	Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug (Investor's Business Daily) -18.53%
04:25PM	These Stocks Moved the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More (Barrons.com)
03:15PM	These Stocks Are Moving the Most Today: Amazon, Tesla, Uber, Affirm, Pinterest, Take-Two, Expedia, Bill, e.l.f. Beauty, and More (Barrons.com)
01:05PM	Why Is Neurocrine Biosciences Stock Trading Lower On Friday? (Benzinga)
08:15AM	Q4 2024 Neurocrine Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
02:23AM	Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ... (GuruFocus.com)
Feb-06-25 05:15PM	Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates (Zacks)
04:27PM	Neurocrine: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 (PR Newswire)
Feb-04-25 12:47PM	Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now (Insider Monkey)
09:15AM	Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures (Zacks)
Jan-30-25 04:01PM	Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results (PR Newswire)
Jan-29-25 10:01AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
Jan-28-25 10:24AM	Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights (Benzinga)
08:30AM	Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults (PR Newswire)
Jan-27-25 04:05PM	Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) (PR Newswire)
Jan-23-25 04:05PM	Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device (PR Newswire)
Jan-21-25 04:05PM	Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism (PR Newswire)
Jan-08-25 08:30AM	Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology and Metabolism (PR Newswire)
08:30AM	Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism (PR Newswire)
Jan-06-25 04:01PM	Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-24-24 03:23PM	Neurocrine Biosciences Stock Sees RS Rating Upgrade (Investor's Business Daily)
Dec-20-24 08:00AM	Neurocrine Biosciences Announces Commercial Availability of CRENESSITY (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia (PR Newswire)
Dec-16-24 04:10PM	Neurocrine Jumps After Snagging FDA Approval For A First-In-Decades Drug (Investor's Business Daily) +5.01%

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Option Exercise	79.02	457	36,112	5,187	Jul 11 05:15 PM
Delaet Ingrid	Chief Regulatory Officer	Jul 10 '25	Sale	135.00	457	61,695	4,730	Jul 11 05:15 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Option Exercise	84.74	59,819	5,069,062	78,108	Jul 11 05:01 PM
Onyia Jude	Chief Scientific Officer	Jul 09 '25	Sale	130.46	59,819	7,803,688	18,289	Jul 11 05:01 PM
INGRID DELAET	Officer	Jul 10 '25	Proposed Sale	133.51	457	61,014		Jul 10 04:32 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Option Exercise	84.74	20,362	1,725,476	38,651	Jul 07 04:10 PM
Onyia Jude	Chief Scientific Officer	Jul 02 '25	Sale	130.13	20,362	2,649,738	18,289	Jul 07 04:10 PM
JUDE ONYIA	Officer	Jul 02 '25	Proposed Sale	128.00	80,181	10,263,168		Jul 02 04:22 PM
GORMAN KEVIN CHARLES	Director	May 27 '25	Sale	120.38	9,613	1,157,211	514,596	May 29 06:15 PM
KEVIN CHARLES GORMAN	Director	May 27 '25	Proposed Sale	120.18	9,613	1,155,290		May 27 04:38 PM
RASTETTER WILLIAM H	Director	May 22 '25	Option Exercise	0.00	2,869	0	40,360	May 22 06:15 PM
POON CHRISTINE A	Director	May 22 '25	Option Exercise	0.00	1,435	0	1,435	May 22 05:32 PM
Sharp Shalini	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:28 PM
SHERWIN STEPHEN A	Director	May 22 '25	Option Exercise	0.00	2,869	0	13,542	May 22 05:26 PM
POPS RICHARD F	Director	May 22 '25	Option Exercise	0.00	2,869	0	34,480	May 22 05:23 PM
MORROW GEORGE J	Director	May 22 '25	Option Exercise	0.00	2,869	0	7,068	May 22 05:20 PM
LYONS GARY A	Director	May 22 '25	Option Exercise	0.00	1,435	0	120,482	May 22 05:18 PM
Norwalk Leslie V	Director	May 22 '25	Option Exercise	0.00	1,435	0	2,429	May 22 05:14 PM
Mercier Johanna	Director	May 22 '25	Option Exercise	0.00	1,435	0	3,535	May 22 05:12 PM
Cooke Julie	Chief Human Resources Officer	May 16 '25	Option Exercise	61.82	6,468	399,852	26,858	May 20 04:43 PM
RASTETTER WILLIAM H	Director	May 05 '25	Option Exercise	42.76	30,000	1,282,800	67,491	May 07 07:05 PM
RASTETTER WILLIAM H	Director	May 05 '25	Sale	110.20	30,000	3,305,952	37,491	May 07 07:05 PM
WILLIAM H. RASTETTER	Officer	May 05 '25	Proposed Sale	109.68	30,000	3,290,400		May 05 04:40 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Option Exercise	0.00	2,910	0	20,945	Feb 14 07:13 PM
Cooke Julie	Chief Human Resources Officer	Feb 13 '25	Sale	116.78	1,551	181,129	19,544	Feb 14 07:13 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Option Exercise	0.00	10,979	0	527,221	Feb 14 06:57 PM
GORMAN KEVIN CHARLES	Director	Feb 13 '25	Sale	116.69	5,844	681,914	521,618	Feb 14 06:57 PM
SHERWIN STEPHEN A	Director	Feb 13 '25	Sale	116.69	13,831	1,613,923	10,673	Feb 14 06:49 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Option Exercise	0.00	4,605	0	36,140	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 13 '25	Sale	116.85	1,718	200,742	34,252	Feb 14 06:42 PM
ROBERTS EIRY	Chief Medical Officer	Feb 14 '25	Sale	115.04	500	57,521	35,640	Feb 14 06:42 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Option Exercise	0.00	5,407	0	19,536	Feb 14 06:35 PM
Onyia Jude	Chief Scientific Officer	Feb 13 '25	Sale	116.79	2,879	336,239	16,846	Feb 14 06:35 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Option Exercise	0.00	4,100	0	44,491	Feb 14 06:26 PM
Lippoldt Darin	Chief Legal Officer	Feb 13 '25	Sale	116.75	2,184	254,992	42,474	Feb 14 06:26 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	141,113	Feb 14 06:20 PM
Gano Kyle	Chief Executive Officer	Feb 13 '25	Sale	116.85	2,558	298,908	138,872	Feb 14 06:20 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Option Exercise	0.00	2,759	0	5,485	Feb 14 06:13 PM
Delaet Ingrid	Chief Regulatory Officer	Feb 13 '25	Sale	116.71	1,471	171,674	4,084	Feb 14 06:13 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Option Exercise	0.00	3,352	0	4,395	Feb 14 06:08 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 13 '25	Sale	116.74	1,785	208,387	2,854	Feb 14 06:08 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Option Exercise	0.00	4,044	0	45,745	Feb 14 06:03 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 13 '25	Sale	116.73	2,154	251,428	43,784	Feb 14 06:03 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Option Exercise	0.00	4,807	0	37,016	Feb 14 06:00 PM
ABERNETHY MATT	Chief Financial Officer	Feb 13 '25	Sale	116.86	2,558	298,923	34,775	Feb 14 06:00 PM
EIRY WYN ROBERTS	Officer	Feb 14 '25	Proposed Sale	115.04	500	57,521		Feb 14 04:12 PM
STEPHEN A SHERWIN	Director	Feb 13 '25	Proposed Sale	117.18	13,831	1,620,717		Feb 13 04:38 PM
MATTHEW ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:38 PM
MATTHEW C ABERNETHY	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
KEVIN CHARLES GORMAN	Director	Feb 13 '25	Proposed Sale	117.18	3,012	352,946		Feb 13 04:37 PM
KYLE W GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,206	141,319		Feb 13 04:37 PM
JULIE SMITH COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:37 PM
ERIC S BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,056	123,742		Feb 13 04:36 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,447	169,559		Feb 13 04:36 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	755	88,471		Feb 13 04:36 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	830	97,259		Feb 13 04:35 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,086	127,257		Feb 13 04:35 PM
EIRY WYN ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	604	70,777		Feb 13 04:35 PM
EIRY ROBERTS	Officer	Feb 13 '25	Proposed Sale	117.18	1,114	130,539		Feb 13 04:34 PM
DARIN LIPPOLDT	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
ERIC BENEVICH	Officer	Feb 13 '25	Proposed Sale	117.18	1,098	128,664		Feb 13 04:34 PM
JUDE ONYIA	Officer	Feb 13 '25	Proposed Sale	117.18	1,432	167,802		Feb 13 04:34 PM
INGRID DELAET	Officer	Feb 13 '25	Proposed Sale	117.18	716	83,901		Feb 13 04:33 PM
DAVID WARREN BOYER	Officer	Feb 13 '25	Proposed Sale	117.18	955	111,907		Feb 13 04:33 PM
JULIE COOKE	Officer	Feb 13 '25	Proposed Sale	117.18	796	93,275		Feb 13 04:33 PM
KYLE GANO	Officer	Feb 13 '25	Proposed Sale	117.18	1,352	158,427		Feb 13 04:32 PM
Kevin Charles Gorman	Director	Feb 13 '25	Proposed Sale	117.18	2,832	331,854		Feb 13 04:31 PM
Cooke Julie	Chief Human Resources Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	19,531	Feb 12 07:00 PM
Cooke Julie	Chief Human Resources Officer	Feb 10 '25	Sale	118.28	700	82,792	18,831	Feb 12 07:00 PM
GORMAN KEVIN CHARLES	Director	Feb 08 '25	Option Exercise	0.00	4,318	0	521,348	Feb 12 06:56 PM
GORMAN KEVIN CHARLES	Director	Feb 10 '25	Sale	118.37	2,274	269,167	519,074	Feb 12 06:56 PM
ROBERTS EIRY	Chief Medical Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	34,233	Feb 12 06:52 PM
ROBERTS EIRY	Chief Medical Officer	Feb 10 '25	Sale	118.22	980	115,853	33,253	Feb 12 06:52 PM
Lippoldt Darin	Chief Legal Officer	Feb 08 '25	Option Exercise	0.00	1,727	0	42,590	Feb 12 06:49 PM
Lippoldt Darin	Chief Legal Officer	Feb 10 '25	Sale	118.25	911	107,727	41,679	Feb 12 06:49 PM
Gano Kyle	Chief Executive Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	138,638	Feb 12 06:48 PM
Gano Kyle	Chief Executive Officer	Feb 10 '25	Sale	118.39	980	116,020	137,658	Feb 12 06:48 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 08 '25	Option Exercise	0.00	1,329	0	2,698	Feb 12 06:46 PM
Boyer David W.	Chief Corp. Affairs Officer	Feb 10 '25	Sale	118.31	700	82,820	1,998	Feb 12 06:46 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	43,779	Feb 12 06:44 PM
BENEVICH ERIC	Chief Commercial Officer	Feb 10 '25	Sale	118.31	980	115,940	42,799	Feb 12 06:44 PM
ABERNETHY MATT	Chief Financial Officer	Feb 08 '25	Option Exercise	0.00	1,860	0	34,541	Feb 12 06:41 PM
ABERNETHY MATT	Chief Financial Officer	Feb 10 '25	Sale	118.27	980	115,909	33,561	Feb 12 06:41 PM
KYLE W GANO	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:33 PM
JULIE SMITH COOKE	Officer	Feb 10 '25	Proposed Sale	122.62	700	85,834		Feb 10 04:33 PM
DAVID WARREN BOYER	Officer	Feb 10 '25	Proposed Sale	122.62	700	85,834		Feb 10 04:33 PM
ERIC BENEVICH	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:32 PM
KEVIN CHARLES GORMAN	Director	Feb 10 '25	Proposed Sale	122.62	2,274	278,838		Feb 10 04:32 PM
DARIN LIPPOLDT	Officer	Feb 10 '25	Proposed Sale	122.62	911	111,707		Feb 10 04:32 PM
EIRY WYN ROBERTS	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:31 PM
MATTHEW C ABERNETHY	Officer	Feb 10 '25	Proposed Sale	122.62	980	120,168		Feb 10 04:30 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '25	Option Exercise	0.00	1,740	0	19,942	Feb 04 06:05 PM
Cooke Julie	Chief Human Resources Officer	Jan 31 '25	Sale	152.89	1,740	266,025	18,202	Feb 04 06:05 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '25	Option Exercise	0.00	5,141	0	519,737	Feb 04 05:58 PM
GORMAN KEVIN CHARLES	Director	Jan 31 '25	Sale	152.92	2,707	413,967	517,030	Feb 04 05:58 PM
ROBERTS EIRY	Chief Medical Officer	Jan 31 '25	Option Exercise	0.00	2,769	0	33,830	Feb 04 05:54 PM
ROBERTS EIRY	Chief Medical Officer	Jan 31 '25	Sale	152.80	1,457	222,636	32,373	Feb 04 05:54 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '25	Option Exercise	0.00	238	0	15,687	Feb 04 05:51 PM
Onyia Jude	Chief Scientific Officer	Jan 31 '25	Sale	152.97	126	19,274	15,561	Feb 04 05:51 PM
Lippoldt Darin	Chief Legal Officer	Jan 31 '25	Option Exercise	0.00	2,373	0	42,113	Feb 04 05:49 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Neurocrine Biosciences, Inc

Upgrade your FINVIZ experience